Nitric oxide increases cyclic GMP levels, AMP-activated protein kinase (AMPK)alpha1-specific activity and glucose transport in human skeletal muscle

TY - JOUR

T1 - Nitric oxide increases cyclic GMP levels, AMP-activated protein kinase (AMPK)alpha1-specific activity and glucose transport in human skeletal muscle

AU - Deshmukh, A S

AU - Long, Y C

AU - de Castro Barbosa, T

AU - Karlsson, H K R

AU - Glund, S

AU - Zavadoski, W J

AU - Gibbs, E M

AU - Koistinen, H A

AU - Wallberg-Henriksson, H

AU - Zierath, J R

PY - 2010/6

Y1 - 2010/6

N2 - Aims/hypothesis: We investigated the direct effect of a nitric oxide donor (spermine NONOate) on glucose transport in isolated human skeletal muscle and L6 skeletal muscle cells. We hypothesised that pharmacological treatment of human skeletal muscle with N-(2-aminoethyl)-N-(2-hydroxy-2-nitrosohydrazino)-1,2- ethylenediamine (spermine NONOate) would increase intracellular cyclic GMP (cGMP) levels and promote glucose transport. Methods: Skeletal muscle strips were prepared from vastus lateralis muscle biopsies obtained from seven healthy men. Muscle strips were incubated in the absence or presence of 5 mmol/l spermine NONOate or 120 nmol/l insulin. The L6 muscle cells were treated with spermine NONOate (20 μmol/l) and incubated in the absence or presence of insulin (120 nmol/l). The direct effect of spermine NONOate and insulin on glucose transport, cGMP levels and signal transduction was determined. Results: In human skeletal muscle, spermine NONOate increased glucose transport 2.4-fold (p∈<∈0.05), concomitant with increased cGMP levels (80-fold, p∈<∈0.001). Phosphorylation of components of the canonical insulin signalling cascade was unaltered by spermine NONOate exposure, implicating an insulin-independent signalling mechanism. Consistent with this, spermine NONOate increased AMP-activated protein kinase (AMPK)-α1-associated activity (1.7-fold, p∈<∈0.05). In L6 muscle cells, spermine NONOate increased glucose uptake (p∈<∈0.01) and glycogen synthesis (p∈<∈0.001), an effect that was in addition to that of insulin. Spermine NONOate also elicited a concomitant increase in AMPK and acetyl-CoA carboxylase phosphorylation. In the presence of the guanylate cyclase inhibitor LY-83583 (10 μmol/l), spermine NONOate had no effect on glycogen synthesis and AMPK-α1 phosphorylation. Conclusions/interpretation: Pharmacological treatment of skeletal muscle with spermine NONOate increases glucose transport via insulin-independent signalling pathways involving increased intracellular cGMP levels and AMPK-α1-associated activity.

AB - Aims/hypothesis: We investigated the direct effect of a nitric oxide donor (spermine NONOate) on glucose transport in isolated human skeletal muscle and L6 skeletal muscle cells. We hypothesised that pharmacological treatment of human skeletal muscle with N-(2-aminoethyl)-N-(2-hydroxy-2-nitrosohydrazino)-1,2- ethylenediamine (spermine NONOate) would increase intracellular cyclic GMP (cGMP) levels and promote glucose transport. Methods: Skeletal muscle strips were prepared from vastus lateralis muscle biopsies obtained from seven healthy men. Muscle strips were incubated in the absence or presence of 5 mmol/l spermine NONOate or 120 nmol/l insulin. The L6 muscle cells were treated with spermine NONOate (20 μmol/l) and incubated in the absence or presence of insulin (120 nmol/l). The direct effect of spermine NONOate and insulin on glucose transport, cGMP levels and signal transduction was determined. Results: In human skeletal muscle, spermine NONOate increased glucose transport 2.4-fold (p∈<∈0.05), concomitant with increased cGMP levels (80-fold, p∈<∈0.001). Phosphorylation of components of the canonical insulin signalling cascade was unaltered by spermine NONOate exposure, implicating an insulin-independent signalling mechanism. Consistent with this, spermine NONOate increased AMP-activated protein kinase (AMPK)-α1-associated activity (1.7-fold, p∈<∈0.05). In L6 muscle cells, spermine NONOate increased glucose uptake (p∈<∈0.01) and glycogen synthesis (p∈<∈0.001), an effect that was in addition to that of insulin. Spermine NONOate also elicited a concomitant increase in AMPK and acetyl-CoA carboxylase phosphorylation. In the presence of the guanylate cyclase inhibitor LY-83583 (10 μmol/l), spermine NONOate had no effect on glycogen synthesis and AMPK-α1 phosphorylation. Conclusions/interpretation: Pharmacological treatment of skeletal muscle with spermine NONOate increases glucose transport via insulin-independent signalling pathways involving increased intracellular cGMP levels and AMPK-α1-associated activity.

KW - AMP-Activated Protein Kinases

KW - Analysis of Variance

KW - Biological Transport

KW - Blotting, Western

KW - Cells, Cultured

KW - Cyclic GMP

KW - Glucose

KW - Humans

KW - Insulin

KW - Male

KW - Middle Aged

KW - Muscle, Skeletal

KW - Nitric Oxide

KW - Nitric Oxide Donors

KW - Phosphorylation

KW - Signal Transduction

KW - Spermine

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

U2 - 10.1007/s00125-010-1716-x

DO - 10.1007/s00125-010-1716-x

M3 - Journal article

C2 - 20349036

SN - 0012-186X

VL - 53

SP - 1142

EP - 1150

JO - Diabetologia

JF - Diabetologia

IS - 6

ER -